We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

AZD5438 in Patients With Advanced Solid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00088790
Recruitment Status : Completed
First Posted : August 5, 2004
Last Update Posted : January 26, 2011
Information provided by:

Brief Summary:
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: AZD5438 Phase 1

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies
Study Start Date : July 2004
Primary Completion Date : December 2005
Study Completion Date : December 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced solid malignancy
  • Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria:

  • Radiotherapy within 3 weeks of the start of treatment
  • Investigational product within the last 3 weeks
  • Systemic cytotoxic anti-cancer therapy within the last 3 weeks
  • Any significant clinical disorder that makes it undesirable for the patient to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00088790

United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, New York
Research Site
New York City, New York, United States
Sponsors and Collaborators

ClinicalTrials.gov Identifier: NCT00088790     History of Changes
Other Study ID Numbers: D0110C00005
First Posted: August 5, 2004    Key Record Dates
Last Update Posted: January 26, 2011
Last Verified: January 2011

Keywords provided by AstraZeneca:
advanced, solid, malignancies

Additional relevant MeSH terms: